The finding that reduced CUL5 gene activity increases CAR-T cell anticancer effects could improve treatment for patients with aggressive cancers such as leukemia, lymphoma, and multiple myeloma.
The finding that reduced CUL5 gene activity increases CAR-T cell anticancer effects could improve treatment for patients with aggressive cancers such as leukemia, lymphoma, and multiple myeloma.